# Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy

> **NCT02019784** · PHASE4 · COMPLETED · sponsor: **King's College Hospital NHS Trust** · enrollment: 38 (actual)

## Conditions studied

- Liver Cirrhosis
- Hepatoencephalopathy, Early Fatal Progressive

## Interventions

- **DRUG:** Rifaximin-α
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT02019784
- **Lead sponsor:** King's College Hospital NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-06
- **Final completion:** 2016-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2016-11-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019784, "Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02019784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*